Stem Cell Cartilage Regeneration Market, by Stem Cell Type (Hematopoietic Stem Cells, Pluripotent Stem Cells, and Mesenchymal Stem Cells), by Treatment (Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, and Others), by End User

Stem Cell Cartilage Regeneration Market, by Stem Cell Type (Hematopoietic Stem Cells, Pluripotent Stem Cells, and Mesenchymal Stem Cells), by Treatment (Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, and Others), by End User (Hospitals & Clinics and Ambulatory Surgical Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

In cartilage regeneration, stem cells have the potential for multiple differentiation and self-replication, making it an ideal choice for use as seed cells. Growing regenerative medicine industry and increasing demand for stem cells in the development of various types of cell therapies are expected to drive growth of the market over the forecast period. Mesenchymal stem cells are the most widely applied stem cells in the field of cartilage regeneration.
Furthermore, adult stem cells have potential to differentiate into cartilage, bone, fat or soft tissue. Stem cell-based therapy has become a key focus in functional replacement of cartilage regeneration. Adult stem cells can be extracted by minimally invasive methods from fat tissue and bone marrow. Fat derived stem cells exhibits an enhanced ability to differentiate into cartilage and are found in higher numbers than bone marrow.
Market Dynamics
Government agencies are focusing on policies to enhance adoption of stem cell therapies, which is expected to drive growth of stem cell cartilage regeneration market over the forecast period. For instance, in December 2016, the 21st Century Cures Act (Cures Act) was signed into law by the U.S. FDA, thereby allowing legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) for patients who need it.
Furthermore, growing engagement of various key players in developing stem cell therapy as a commercially viable, safer, more efficient, and less expensive therapeutic agent for cartilage regeneration is expected to drive growth of the global stem cell cartilage regeneration market. For instance, in January 2021, a group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which previously was incurable and had no effective therapies. Following the first in-human clinical trial at Osaka University Hospital, the surgery of the first patient was performed in the Phase III clinical study to confirm efficacy and safety of this therapy.
Moreover, growing osteoarthritis incidence among the global population is expected to drive adoption of stem cell cartilage regeneration therapy. For instance, according to the Arthritis Foundation, November 2017 data findings, with the increase in global geriatric population, degenerative disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050.
Key features of the study:
This report provides in-depth analysis of the market, global stem cell cartilage regeneration market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global stem cell cartilage regeneration market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies.
Key players covered as a part of this study include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, market expansions, and marketing tactics.
The global stem cell cartilage regeneration market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of reprocessed medical devices, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Stem Cell Cartilage Regeneration Market, By Stem Cell Type:
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs)
Global Stem Cell Cartilage Regeneration Market, By Treatment:
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
Global Stem Cell Cartilage Regeneration Market, By End User:
Hospitals & Clinics
Ambulatory Surgical Centers
Global Stem Cell Cartilage Regeneration Market, By Region :
North America
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country:
U.S.
Canada
Latin America
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country:
GCC
Israel
Rest of Middle East
Africa
By Stem Cell Type
Hematopoietic Stem Cells (HSCs)
Pluripotent Stem Cells (iPSC/ESCs)
Mesenchymal Stem Cells (MSCs
Gastroenterology
By Treatment
Microfracture
Osteochondral Transplant
Autologous Chondrocyte Implantation
Stem Cell Injections
By End User
Hospitals & Clinics
Ambulatory Surgical Centers
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Theracell Advanced Biotechnology Ltd *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Orthocell Ltd.
Xintela AB
CellGenix GmbH
Merck KGaA
Osiris Therapeutics, Inc.
BioTissue SA
Vericel Corporation
“*” marked represents similar segmentation in other categories in the respective section.